Cargando…

Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma

BACKGROUND: Nivolumab is approved in Japan as a second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) resistant to fluoropyrimidine and platinum-based drugs. It is also used in adjuvant and primary postoperative therapies. This study aimed to report real-world da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohsawa, Manato, Hamai, Yoichi, Emi, Manabu, Ibuki, Yuta, Kurokawa, Tomoaki, Yoshikawa, Toru, Hirohata, Ryosuke, Kitasaki, Nao, Okada, Morihito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151017/ https://www.ncbi.nlm.nih.gov/pubmed/37139161 http://dx.doi.org/10.3389/fonc.2023.1126536

Ejemplares similares

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2023)

Recurrent esophageal adenocarcinoma derived from ectopic gastric mucosa: A case report
por: Kitasaki, Nao, et al.
Publicado: (2022)

Risk factors for aortoesophageal fistula in cT4b esophageal squamous cell carcinoma after definitive radiation therapy
por: Hirohata, Ryosuke, et al.
Publicado: (2023)

Thoracoscopic double-flap reconstruction for esophagogastric junction cancer: A case report
por: Ohsawa, Manato, et al.
Publicado: (2020)

Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma
por: Ibuki, Yuta, et al.
Publicado: (2020)

Three-step surgical treatment of aortoesophageal fistula after thoracic endovascular aortic repair: A case report
por: Kamigaichi, Atsushi, et al.
Publicado: (2019)

Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
por: Ochi, Masanori, et al.
Publicado: (2020)

Role of FDG-PET/CT in prediction of pathological tumor response and survival after trimodality therapy for esophageal squamous cell carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2015)

Emergency escape surgery for a gastro-bronchial fistula with respiratory failure that developed after esophagectomy
por: Ibuki, Yuta, et al.
Publicado: (2014)

Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report
por: Hamai, Yoichi, et al.
Publicado: (2012)

Leukocyte Telomeric G-Tail Length Shortening Is Associated with Esophageal Cancer Recurrence
por: Han, Jiayan, et al.
Publicado: (2022)

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3
por: Chin, Keisho, et al.
Publicado: (2022)

Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma
por: Murakami, Yuji, et al.
Publicado: (2018)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
por: Toyota, Satoshi, et al.
Publicado: (2020)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
por: Mimura, Kosaku, et al.
Publicado: (2023)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
por: Sekido, Katsuhisa, et al.
Publicado: (2023)

Nivolumab in the treatment of malignant melanoma: review of the literature
por: Mashima, Emi, et al.
Publicado: (2015)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
por: Aomatsu, Naoki, et al.
Publicado: (2014)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2020)

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study
por: Sato, Sho, et al.
Publicado: (2021)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: Anoop, T M, et al.
Publicado: (2022)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Pathological complete response of multiple liver metastases from colon cancer successfully treated with conversion surgery: A case report
por: Kitasaki, Nao, et al.
Publicado: (2023)

Taxane-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2015)

Sex Differences in Taxane Toxicities
por: Chmielewski, Nicole N., et al.
Publicado: (2022)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience
por: Kao, Ming-Wei, et al.
Publicado: (2023)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
por: Tsunemitsu, Ryosuke, et al.
Publicado: (2023)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience
por: Kubota, Yohei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rpo77h7ii9d6amqmb3sahb3re0